DNA Encoded Library (DEL) Screening Services
in partnership with
Aurigene offers DEL screening services for small molecules in collaboration with Vipergen. The platform adds additional flexibility to our core Integrated Drug Discovery (IDD) solution.
Overview of DEL Screening services
Aurigene offers state-of-the-art DNA Encoded Library (DEL) screening services for small molecules, in strategic collaboration with Vipergen, to accelerate innovation in drug discovery by increasing success rates and reducing timelines through screening a billion+ small-molecule compounds.
The unique platform enables screening not only using a purified drug target protein but also in a living cell. Screening in a living cell mimics the physiological conditions more accurately.
The collaboration aims to co-market and offer DEL screening technologies to global customers as a standalone service or as an integrated drug discovery service. Combining Vipergen’s DEL technology with Aurigene’s 20+ years of experience in synthesis, protein generation, assay development, and testing of compounds in both in-vitro & in-vivo setup enables us to service the customer end-to-end.
Screening in a living cell (DEL in cell)
Leverages Cellular Binder Trap Enrichment®(cBTE) technology. It is the first and only technology for screening of DELs inside a living cell.
The advantage of screening inside a cell includes:
- Screening under physiologically relevant conditions
- Lower attrition rate
- No need for highly purified target protein
- Broader protein target space
Screening on purified protein
uses homogeneous screening method, Binder Trap Enrichment® (BTE), water-in-oil emulsion technology to isolate individual ligand-target complexes
The specific benefits of BTE include:
- High fidelity – low false positive rate
- Generally applicable across disease areas and target classes
- Applicable to difficult targets (including PPIs and protein complexes)
- Target-ligand residence time based discovery (unique capability)
- Affinity based discovery
- Instant SAR
- Instant selectivity – multiplexed screening of target and anti-targets (unique capability)
- Low amounts of protein required (μg)
Yoctoreactor libraries
The Yoctoreactor libraries containing hundreds of millions of DNA-encoded drug-like small molecules are synthesized in a single tube-format by drawing on the self-assembly of complementary DNA into DNA junctions. Chemical building blocks (BBs) are brought into close proximity which facilitates chemical reaction and the attached DNA ultimately encodes the final product.
The overall design has favorable implications for the scope and reliability of the chemistry, the stability of the structure, and, ultimately, the capability for addressing the most challenging targets. 100% correspondence between code and synthesized compound is ensured by purification steps using the DNA as purification handle after each chemical step. Learn more
Homogenous assay ability to multiplex
A homogeneous screening method for DELs which uses water-in-oil emulsion technology to isolate individual ligand-target complexes. Ligands to a protein target are identified by trapping binding pairs (DNA-labelled protein target and DEL ligand) in emulsion droplets during dissociation dominated kinetics. Once trapped, the target and ligand DNA are joined by ligation, thus preserving the binding information.
What next after screening?
- Resynthesis of compounds (without DNA tag), confirmation of hits in orthogonal assay
- Optimize the hits using CADD, AIDD and traditional approaches
- Lead optimization and candidate nomination
The identified potential hits from the screening will be dedicated to the customer and removed from the library for other customers.
For more detailed information about our DEL screening services, visit Vipergen's page on DEL technology.
Why Aurigene DNA Encoded Library (DEL) Screening Services?
In cell screening: Physiological relevant screening conditions
High success rate: ~80% for even difficult targets
Low false positive rate: high fidelity process
Integrated drug discovery capabilities: Aurigene’s IDD and commercial offerings enable one-stop solution
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market